|
|
???tair.name??? >
???browser.page.title.author???
|
"dai c y"???jsp.browse.items-by-author.description???
Showing items 51-60 of 170 (17 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2022-01-07T06:05:52Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; CHIH-YUAN LEE; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-07T06:05:50Z |
The autophagy marker LC3 strongly predicts immediate mortality after surgical resection for hepatocellular carcinoma
|
Lin C.-W.; Lin C.-C.; Lee P.-H.; Lo G.-H.; Hsieh P.-M.; Koh K.W.; CHIH-YUAN LEE; Chen Y.-L.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Chen Y.-S.; Yu M.-L. |
| 國立成功大學 |
2022 |
Time-dependent effects of storage at –80 °C on the stability of butyrylcholinesterase activity in human serum
|
Huang, C.-H.;Chang, Y.-T.;Severance, Severance S.;Feng, J.-Y.;Hou, S.-Y.;Gong, M.-M.;Hwang, C.-C.;Dai, C.Y.;Wang, J.-J.;Wang, T.-P. |
| 國立成功大學 |
2022 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
|
Lo, C.-C.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Chuang, W.-L.;Lin, H.-C.;Kao, J.-H.;Yu, M.-L.;investigators, TACR |
| 國立成功大學 |
2022 |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang, C.-F.;Tseng, K.-C.;Cheng, P.-N.;Hung, C.-H.;Lo, C.-C.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Chen, Chen C.-H.;Lee, P.-L.;Lin, C.-Y.;Kuo, H.-T.;Chen, Chen C.-T.;Yang, C.-C.;Huang, J.-F.;Tai, C.-M.;Hu, J.-T.;Lin, C.-L.;Su, W.-W.;Tsai, W.-L.;Huang, Y.-H.;Cheng, Cheng C.-Y.;Lin, C.-L.;Wang, C.-C.;Yang, S.-S.;Mo, L.-R.;Chen, G.-Y.;Chang, Chang C.-C.;Wang, S.-J.;Huang, C.-S.;Hsieh, T.-Y.;Lin, C.-W.;Lee, T.-H.;Chong, L.-W.;Huang, C.-W.;Chang, S.-N.;Tsai, M.-C.;Hsu, S.-J.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Lin, H.-C.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Chuang, W.-L.;Chen, Chen C.-Y.;Yu, M.-L. |
| 國立成功大學 |
2022 |
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
|
Chen, Y.-C.;Chang, T.-S.;Chen, Chen C.-H.;Cheng, P.-N.;Lo, C.-C.;Mo, L.-R.;Chen, Chen C.-T.;Huang, C.-F.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L.;investigators, on behalf of TACR |
| 國立成功大學 |
2022 |
Sofosbuvir/Velpatasvir for Hepatitis�C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng, P.-N.;Mo, L.-R.;Chen, Chen C.-T.;Chen, Chen C.-Y.;Huang, C.-F.;Kuo, H.-T.;Lo, C.-C.;Tseng, K.-C.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Chou, K.-H.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Cheng, Cheng C.-Y.;Tsai, M.-C.;Liu, C.-J.;Dai, C.-Y.;Lin, H.-C.;Kao, J.-H.;Chuang, W.-L.;Yu, M.-L.;investigators, TACR |
| 臺大學術典藏 |
2021-09-27T05:32:41Z |
222?days without COVID in Taiwan: what are the reasons for this success?
|
Dai C.-Y.; Dai T.-H.; WANG-HUEI SHENG; Ho C.-K. |
| 臺大學術典藏 |
2021-09-04T06:12:14Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; JIA-HORNG KAO; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:12Z |
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses
|
Yeh M.-L.; Hung C.-H.; Huang J.-F.; Liu C.-J.; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
Showing items 51-60 of 170 (17 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
|
